Christina Ai-Kheng Kim, MD, FRCPC

Email this Researcher

Christina Ai-Kheng Kim, MD, FRCPC

Email this Researcher

Research Discipline(s): Clinical

Primary Title: Medical Oncologist, CancerCare Manitoba

Additional Titles & Affiliations: Associate Professor, Department of Internal Medicine, Section of Medical Oncology and Hematology, Max Rady College of Medicine, University of Manitoba


Pancreatic Cancer, Hepatobiliary Cancers, Colorectal Cancer, Lynch Syndrome, Breast Cancer, Palliative Care, Symptom Burden, Quality of Life.

Research Summary

Dr. Kim is an expert in the diagnosis and management of gastrointestinal and breast cancers. She is passionate about asking clinical questions which drive research to improve care and quality of life for patients and families facing a cancer diagnosis. Dr. Kim has a particular interest in pancreatic cancer, including real world treatment patterns, outcomes, chemotherapy-related toxicity, quality of life and early palliative care. Dr Kim has been an advocate for establishing the early palliative care initiative for patients with an advanced cancer diagnosis in Manitoba. She is clinical co-lead of the hereditary gastrointestinal cancer clinic and is collaborating with other investigators in the development of a registry to improve outcomes for Manitobans with Lynch Syndrome.


Content coming soon

Research Biography

Dr. Kim is an associate professor of internal medicine at the Max Rady College of Medicine at the University of Manitoba and a medical oncologist at CancerCare Manitoba. She was born and raised in Alberta and attended medical school at theUniversity of Manitoba. After completion of medical school, she went on to complete an internal medicine residency at the University of British Columbia, followed by a medical oncology subspeciality residency at the University of Alberta. Dr. Kim was awarded a Canadian Institute of Health Research (CIHR) and Canadian Association of Medical Oncologists (CAMO)-funded fellowship focused on symptom burden and prognostic and predictive markers in pancreatic cancer. Dr. Kim's is a member of the gastrointestinal and breast disease site groups at CancerCare Manitoba. Clinical practice informs her research, and she is passionate about using clinical research to improve care for patients.


  • Winnipeg Foundation Martha Donovan Fund – Women’s leadership development award 2022/3
  • Canadian Institute of Health Research (CIHR)/Canadian Association of Medical Oncologists (CAMO) Fellowship award, 2013-2014
  • Novartis Oncology Young Investigators Award (NOYCIA), 2009
  • Medical Oncology & Hematology Excellence in Research Award (2019)
    Email this Researcher
    Find a Researcher

    Featured Publications

    • Rothenmund H, Lambert P, Khan D, Kim CA, Sharma B, Serfas K, Chodirker B, Singh H. Province-Wide Ascertainment of Lynch Syndrome in Manitoba. Clin Gastroenterol Hepatol. 2023 Oct 23:S1542-3565(23)00847-9. doi: 10.1016/j.cgh.2023.10.005. Epub ahead of print. PMID: 37879520.
    • Lelond S, Kim CA. Letter to the Editor: Early Palliative Care Is Not Early Enough. J Palliat Med. 2023 Oct;26(10):1313-1314. doi: 10.1089/jpm.2023.0410. PMID: 37788467.
    • McAndrew EN, Graham J, Dufault B, Desautels DN, Kim CA. Long-term Survival Among Patients With De Novo Human Epidermal Growth Receptor 2-Positive Metastatic Breast Cancer in Manitoba. Am J Clin Oncol. 2023 Dec 4. doi: 10.1097/COC.0000000000001068. Epub ahead of print. PMID: 38047455
    • Snyder RA, Burtness B, Cho M, Del Rivero J, Doroshow DB, Hitchcock KE, Kalyan A, Kim CA, Lukovic J, Parikh AR, Sanford NN, Singh B, Shen C, Shroff RT, Vijayvergia N, Goodman KA, Kunz PL. The Room Where It Happens: Addressing Diversity, Equity, and Inclusion in NCTN Clinical Trial Leadership. J Natl Cancer Inst. 2023 Jun 26:djad121. doi: 10.1093/jnci/djad121. Epub ahead of print. PMID: 37364007.
    • Kim CA, Lelond S, Daeninck PJ, Rabbani R, Lix L, McClement S, Chochinov HM, Goldenberg BA. The impact of early palliative care on the quality of life of patients with advanced pancreatic cancer: The IMPERATIVE case-crossover study. Support Care Cancer 31, 250 (2023).
    • Stone JK, Winter R, Khan D, Rothenmund H, Klein J, Chodirker B, Wightman R, Kim CA, Nugent Z, Singh H. A Canadian Provincial Screening Program for Lynch Syndrome. Am J Gastroenterol. 2023 Feb 1;118(2):345-353. doi: 10.14309/ajg.0000000000002059. Epub 2022 Oct 11. PMID: 36219179.
    • Renouf DJ, Loree JM, Knox JJ, Topham JT, Kavan P, Jonker D, Welch S, Couture F, Lemay F, Tehfe M, Harb M, Aucoin N, Ko YJ, Tang PA, Ramjeesingh R, Meyers BM, Kim CA, Du P, Jia S, Schaeffer DF, Gill S, Tu D, O'Callaghan CJ. The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma. Nat Commun. 2022 Aug 26;13(1):5020.
    • McAndrew EN, Zhang H, Lambert P, Rittberg R, Dawe DE, Kim CA. Treatment patterns, toxicity and outcomes of older adults with advanced pancreatic cancer receiving first-line palliative chemotherapy. American Journal of Clinical Oncology. 2022 Feb 1;45(2):55-60. doi: 10.1097/COC.0000000000000882.
    • Lelond, S, Ward J, Lambert PJ, Kim CA. Symptom Burden of Patients with Advanced Pancreas Cancer (APC): A Provincial Cancer Institute Observational Study. Curr. Oncol. 2021, 28(4), 2789-2800

    Publications List

    Email this Researcher
    Find a Researcher